

What's new in pharmaceutical innovation?



28 New Medicines Approved in 2005

"New Treatments, New Cures"

LUNCH BRIEFING

Monday, February 27, 2006

12:00 p.m. - 1:00 p.m.

Rayburn House Office Building, B-339

The Food and Drug Administration approved **28** new innovative treatments this past year for some of the leading causes of death and illness. Two of the new drugs that will be highlighted during this briefing include:

BYETTA[®] (exenatide) injection (Amylin Pharmaceuticals, Inc. and Eli Lilly and Company) BYETTA is an injectable agent – derived from the salivary secretions of the Gila monster – that improves blood glucose in patients with type 2 diabetes. Unlike other diabetes medicines that can cause weight gain, patients taking BYETTA were shown to have lost weight.

AND

NEXAVAR[®] (BAYER) - Nexavar, an oral multi-kinase inhibitor co-developed and marketed in the U.S. by Bayer Pharmaceuticals Corporation and Onyx Inc, is the first new drug approved in over 12 years to treat adults with advanced renal cell carcinoma, or Kidney Cancer.

Please join us over lunch to learn more from researchers, doctors and patients who have first-hand experience with these exciting, new medical achievements and learn more about our new informational resource: www.innovation.org.

RSVP: 835-3434 or Inewell@phrma.org

Sponsored by:



The Pharmaceutical Research and Manufacturers of America